Kinarus Therapeutics
Kinarus Therapeutics Holding AG is a Swiss-domiciled holding entity with naming associated to a biopharmaceutical company; its primary web domain is currently parked and no active products, customers, or operations are documented in available data.
- Company typePrivate
- Founded1997
- HeadquartersLiestal, Switzerland
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
Kinarus Therapeutics firmographics
Firmographics- Name
- Kinarus Therapeutics
- Legal name
- Kinarus Therapeutics Holding Ag
- Website
- https://kinarus.com
- Company type
- Private
- Founded year
- 1997
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Kinarus Therapeutics Holding AG is a Swiss-domiciled holding entity with naming associated to a biopharmaceutical company; its primary web domain is currently parked and no active products, customers, or operations are documented in available data.
- Ownership category
- akta.pro rank
Kinarus Therapeutics industry classification
Industry- Product category
- Biopharmaceutical Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Management of Companies and Enterprises (551)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)
Keywords
Where Kinarus Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Liestal
- HQ country
- Switzerland
- HQ region
- Europe
Markets served
Kinarus Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
Kinarus Therapeutics product offering
Product offeringCore offering
The company operates under the legal name Kinarus Therapeutics Holding Ag, with a related search reference to "Kinarus Biopharmaceutical Company." This indicates the entity is engaged in the biopharmaceutical therapeutics field. However, no specific therapeutic candidates, product pipeline, indications, mechanisms of action, or commercial offerings are documented in the available source material, as the company website (kinarus.com) is parked with GoDaddy and contains no active product content.
Differentiator
Problem solved
Functional benefit
Companies that use Kinarus Therapeutics
Customer profileIdeal customer profiles1 record
Kinarus Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Kinarus Therapeutics competitors and assessment
Company assessmentDirect peers
- Pliant Therapeutics: Clinical-stage biopharmaceutical company developing small-molecule therapies for fibrotic diseases, including idiopathic pulmonary fibrosis — directly comparable therapeutic focus to Kinarus's known fibrosis pipeline.
- FibroGen: Biotech developing small-molecule therapeutics for serious diseases, historically with a focus on fibrosis and ophthalmology — overlapping therapeutic areas with Kinarus's reported IPF and wet AMD programs.
- Galapagos NV: European clinical-stage biopharmaceutical company developing small-molecule therapies in inflammation and fibrosis, including IPF — directly comparable modality and indication mix.
- Blade Therapeutics: Clinical-stage biotech developing small-molecule drugs for fibrotic diseases including IPF — closely comparable small-molecule fibrosis strategy.
Broad incumbents
- Boehringer Ingelheim: Large established biopharma with Ofev (nintedanib), a leading approved small-molecule IPF therapy; operates broadly in respiratory and fibrotic diseases that intersect with Kinarus's focus.
- Roche: Swiss-headquartered incumbent with a major ophthalmology franchise including Lucentis for wet AMD and a broader small-molecule and biologics portfolio — broadly comparable geography and therapeutic exposure.
- Novartis: Swiss-headquartered incumbent with a major ophthalmology franchise (e.g., Beovu for wet AMD) and broader small-molecule capabilities — comparable jurisdiction and therapeutic-area exposure.
- United Therapeutics: Diversified biopharma with historical involvement in pulmonary and fibrotic disease programs — adjacent therapeutic-area overlap with Kinarus's fibrosis focus.
Emerging players
- Adverum Biotechnologies: Clinical-stage gene therapy company developing treatments for wet AMD — overlapping indication to Kinarus's ophthalmology work but using a different modality (gene therapy).
- REGENXBIO: Clinical-stage biotech developing AAV-based gene therapies including programs for wet AMD — overlapping ophthalmology indication though different therapeutic modality.
Market position
Customer concentration
Kinarus Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Kinarus Therapeutics leadership team
Management profileNumber of profiles
Kinarus Therapeutics funding detail
Funding detailFunding overview
Funding rounds12 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Kinarus Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Kinarus Therapeutics
What does Kinarus Therapeutics do?
The company operates under the legal name Kinarus Therapeutics Holding Ag, with a related search reference to "Kinarus Biopharmaceutical Company." This indicates the entity is engaged in the biopharmaceutical therapeutics field. However, no specific therapeutic candidates, product pipeline, indications, mechanisms of action, or commercial offerings are documented in the available source material, as the company website (kinarus.com) is parked with GoDaddy and contains no active product content.
When was Kinarus Therapeutics founded?
Kinarus Therapeutics was founded in 1997. It employs 1 to 10 people.
Where is Kinarus Therapeutics based?
Kinarus Therapeutics is headquartered in Liestal, Switzerland, in the Europe region.
Who are Kinarus Therapeutics's main competitors?
Direct peers on record are Pliant Therapeutics, FibroGen, Galapagos NV and Blade Therapeutics. Broad incumbents are Boehringer Ingelheim, Roche, Novartis and United Therapeutics. Emerging players are Adverum Biotechnologies and REGENXBIO.
Does Kinarus Therapeutics have an API?
No public API is recorded for Kinarus Therapeutics.
What industry is Kinarus Therapeutics in?
Kinarus Therapeutics's product category is Biopharmaceutical Therapeutics. Its primary akta.pro industry code is HLAGAHAM, Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC). Its NAICS code is 541714 and its SIC code is 8731.